Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | OC1CN(C1)C(=O)CC1(C2CC3CC1CC(C2)C3O)c1ccc(cc1)-c1ccc(F)cc1 |TLB:12:11:8.13.14:16,7:8:16:10.11.17,19:8:10.12.11:14.15.16,THB:18:17:8.13.14:16,12:13:16:10.11.17,17:11:8:14.15.16,17:15:8:10.12.11,7:8:10.12.11:14.15.16,19:8:16:10.11.17,(5.77,-1.2,;6.92,-2.24,;8.46,-2.16,;8.53,-3.7,;7,-3.78,;9.68,-4.73,;9.36,-6.24,;11.15,-4.26,;12.29,-5.3,;13.49,-4.02,;14.82,-4.5,;16.22,-4.16,;15.2,-5.44,;13.79,-4.87,;13.78,-3.28,;14.83,-2.05,;13.48,-2.53,;16.23,-2.63,;17.52,-1.78,;12.27,-6.84,;10.94,-7.58,;10.92,-9.12,;12.24,-9.91,;13.59,-9.14,;13.6,-7.61,;12.23,-11.45,;10.89,-12.21,;10.87,-13.75,;12.2,-14.54,;12.19,-16.08,;13.55,-13.77,;13.56,-12.23,)| |